Table 3. Xenodiagnosis carried out with heparinized peripheral blood of immunosuppressed Leishmania infantum infected patients who attended the hospital for follow-up and prophylaxis or secondary treatment of leishmaniasis (N = 3).

Patient	Age in years	Sampling date	rK39 ICT	PCR	qPCR Parasites/μl	Dissected/ infected flies	IXD	CD4+ 106/l	Viral load Copies/ml	Treatment/ secondary prophylaxis status	Clinical status
24	83	28/04/2016	+	+	4360	36/11 (30.6%)	+	ND	NA	Before LT	Immunosu- ppressed, multiple myeloma, SVL
	83	07/06/2016	+	–	0	86/0	–	ND	NA	Control Post-LT with LAB
	83	17/10/2016	+	–	0	72/0	–	ND	NA
25	40	01/07/2015	+	+	111.6	81/8 (9.9%)	+	122	<20	Before SPL	Immunosu-ppressed, HIV/ L. infantum coinfected, AL
	40	21/10/2015	+	+	148.8	71/18 (25.4%)	+	135	58	3 months after finish SPL with LAB
	41	04/11/2015	+	+	608.4	105/51 (48.6%)	+	ND	107	5 months after finish SPL with LAB
	41	09/12/2015	+	+	48.2	99/0	– a	168	33	Just after 29 days of LT with M+F
	41	17/02/2016	+	+	1104	103/20 (19.4%)	+	112	<20	2 months under SPL with MA+F
	41	13/04/2016	+	+	824	112/9 (8.0%)	+	121	<20	4 months under SPL with MA+F
	42	11/11/2016	+	+	658	56/2 (3.6%)	+	133	<20	1 year under SPL with MA+F
26	50	24/04/2015	+	+	131.8	ND	ND	78	204	3 days after the start of LT with LAB	Immunosu-ppressed HIV/ L. infantum coinfected
	50	10/06/2015	+	–	0	108/0	–	121	85	Just after 29 days of LT with MA+F
	50	21/10/2015	+	–	0	100/0	–	135	<20	14 weeks under LT with MA+F
	51	27/11/2015	+	–	0	103/0	–	204	<20	2 weeks under SPL with LAB+F
	51	15/06/2016	+	–	0	80/0	–	224	<20	6 months under SPL with MA+F

AL, asymptomatic leishmaniasis; F, fluconazole; ICT, immunochromatographic test; IXD, indirect xenodiagnosis; LAB, liposomal amphotericin B; LT, leishmaniasis treatment; M, miltefosine; MA, meglumine antimoniate; NA, not applicable; ND, not done; SPL, secondary prophylaxis of leishmaniasis, SVL, symptomatic visceral leishmaniasis.

^a Haemolyzed blood.